These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24176722)

  • 1. [Impact of sugammadex on neuromuscular blocking agents use: a multicentric, pharmaco-epidemiologic study in French university hospitals and military hospitals].
    Beny K; Piriou V; Dussart C; Hénaine R; Aulagner G; Armoiry X;
    Ann Fr Anesth Reanim; 2013 Dec; 32(12):838-43. PubMed ID: 24176722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experience on the use of sugammadex in a French university hospital].
    Beny K; Mirabaud AF; Piriou V; Aulagner G; Armoiry X
    Ann Fr Anesth Reanim; 2012 Jun; 31(6):568-9. PubMed ID: 22543096
    [No Abstract]   [Full Text] [Related]  

  • 3. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use.
    Della Rocca G; Di Marco P; Beretta L; De Gaudio AR; Ori C; Mastronardi P
    Minerva Anestesiol; 2013 Jun; 79(6):661-6. PubMed ID: 23192221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Nonirritating Concentrations of Neuromuscular Blocking Agents and Related Compounds.
    Gonzalez-Estrada A; Carrillo-Martin I; Morgenstern-Kaplan D; Garzon-Siatoya WT; Renew JR; Hernandez-Torres V; Volcheck GW
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):466-473.e5. PubMed ID: 36108924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugammadex approved to reverse NMBA effects.
    Thompson CA
    Am J Health Syst Pharm; 2016 Feb; 73(3):100. PubMed ID: 26796899
    [No Abstract]   [Full Text] [Related]  

  • 6. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs.
    Ledowski T; Hillyard S; Kozman A; Johnston F; Gillies E; Greenaway M; Kyle BC
    Anaesth Intensive Care; 2012 Mar; 40(2):340-3. PubMed ID: 22417031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
    Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of quantitative versus qualitative neuromuscular blockade monitoring on rocuronium consumption in patients undergoing abdominal and gynecological surgery: a retrospective cohort study.
    Blum LV; Steeger E; Iken S; Lotz G; Zinn S; Piekarski F; Zacharowski K; Raimann FJ
    J Clin Monit Comput; 2023 Apr; 37(2):509-516. PubMed ID: 35986228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
    Palsen S; Wu A; Beutler SS; Gimlich R; Yang HK; Urman RD
    J Clin Monit Comput; 2019 Jun; 33(3):455-462. PubMed ID: 30094585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The feasibility of sugammadex for general anesthesia and facial nerve monitoring in patients undergoing parotid surgery.
    Lu IC; Chang PY; Su MP; Chen PN; Chen HY; Chiang FY; Wu CW
    Kaohsiung J Med Sci; 2017 Aug; 33(8):400-404. PubMed ID: 28811009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concept behind sugammadex.
    Epemolu O; Bom A
    Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of the development of antagonists for neuromuscular blocking agents.
    Suzuki K; Takazawa T; Saito S
    J Anesth; 2020 Oct; 34(5):723-728. PubMed ID: 32766960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.
    Schaller SJ; Lewald H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1097-108. PubMed ID: 27463265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sugammadex: something new to improve patient safety or simply a gadget?].
    Plaud B
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S64-9. PubMed ID: 19887280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugammadex given for rocuronium-induced neuromuscular blockade in infants: a retrospectıve study.
    Ozmete O; Bali C; Cok OY; Turk HE; Ozyilkan NB; Civi S; Aribogan A
    J Clin Anesth; 2016 Dec; 35():497-501. PubMed ID: 27871583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sugammadex for reversal of neuromuscular blockade in 2 patients requiring intraoperative neurophysiological monitoring.
    Reid S; Shields MO; Luney SR
    J Neurosurg Anesthesiol; 2011 Jan; 23(1):56-7. PubMed ID: 21248496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.